



Source details

Biomedical Reports

Scopus coverage years: from 2014 to Present

Publisher: Spandidos Publications

ISSN: 2049-9434 E-ISSN: 2049-9442

Subject area:

- Pharmacology, Toxicology and Pharmaceutics: General Pharmacology, Toxicology and Pharmaceutics
- Biochemistry, Genetics and Molecular Biology: General Biochemistry, Genetics and Molecular Biology
- Neuroscience: General Neuroscience

Source type: Journal

CiteScore 2021 **3.9**

SJR 2021 **0.488**

SNIP 2021 **0.742**

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

$$3.9 = \frac{1,725 \text{ Citations 2018 - 2021}}{446 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$3.1 = \frac{1,203 \text{ Citations to date}}{383 \text{ Documents to date}}$$

Last updated on 05 October, 2022 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#20/74	73rd
General Pharmacology, Toxicology and Pharmaceutics		
Biochemistry, Genetics and Molecular Biology	#81/204	60th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home

Journal Rankings

Country Rankings

Viz Tools

Help

About Us



Intl. J of Distrib. Sens. Net

Open

Hindawi

Biomedical Reports

COUNTRY

Greece



Universities and research institutions in Greece

SUBJECT AREA AND CATEGORY

- Biochemistry, Genetics and Molecular Biology
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- Medicine (miscellaneous)
- Neuroscience (miscellaneous)
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

PUBLISHER

Spandidos Publications

H-INDEX

29

PUBLICATION TYPE

Journals

ISSN

20499434, 20499442

COVERAGE

2014-2021

INFORMATION

[Homepage](#)

[How to publish in this journal](#)



Advances in Civil Eng. Papers


Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us Hindawi

Advances in Civil Eng. Paper

Open

SCOPE


Biomedical Reports is a monthly, peer-reviewed journal, dedicated to publishing research across all fields of biology and medicine, including pharmacology, pathology, gene therapy, genetics, microbiology, neurosciences, infectious diseases, molecular cardiology and molecular surgery. The journal provides a home for original research, case reports and review articles.

 Join the conversation about this journal

Intl. J of Distrib. Sens. Net

Op

Hindawi

 Quartiles



Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us
Hindawi

Intl. J of Distrib. Sens. Net


Op

Hindawi


FIND SIMILAR JOURNALS ?

<p>1 Experimental and Therapeutic Medicine GRC</p> <p>79% similarity</p>	<p>2 International Journal of Medical Sciences AUS</p> <p>78% similarity</p>	<p>3 Bioscience Reports GBR</p> <p>77% similarity</p>	<p>4 Molecular M GRC</p> <p>7 sir</p>
--	--	---	---


SJR




Total Documents




Total Cites Self-Cites



Citations per document





External Cites per Doc Cites per Doc



Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us
Hindawi



Biomedical Reports

Q2 Biochemistry, Genetics and Molecular Biology... best quartile

SJR 2021 0.49

powered by scimagojr.com


← Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scimaç`

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool.**



Metrics based on Scopus® data as of April 2022

E Ekaterina 6 months ago

Dear Sirs,

I would like to know what is the Quartile of this journal in 2021? Thank you very much in advance for your kind reply.

reply

Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us Hindawi



Dear Ekaterina,

Thank you for contacting us. Our data come from Scopus, they annually send us an update of the data. This update is sent to us around April / May every year. The SJR for 2020 was released on 17 May 2021. Therefore, the indicators for 2021 will be available in May/June 2022 and before that date we can't know what will happen with this journal.
Best Regards, SCImago Team

L **Lucia Procopciuc** 12 months ago

I have an article published in your journal Biomedical Reports. I want to know the impact factor in Web of Science for 2021?

Thank you

reply



Melanie Ortiz 12 months ago

SCImago Team

Dear Lucia, thank you very much for your comment. SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR (Check it on our website). We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

S **Shiha** 1 year ago

Is this Open Access Journal? Should we pay to get published through this journal?
Thanks.

Shiha

reply



Melanie Ortiz 1 year ago

SCImago Team

Dear Shiha,
Thank you for contacting us.
We suggest you visit the journal's homepage or contact the journal's editorial staff, so they could inform you more deeply.
Best Regards, SCImago Team

Leave a comment

Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us
Hindawi



I'm not a robot
reCAPTCHA
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1, 1, 106)

Edit Cookie Consent



Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper by Publishing With Us
Hindawi




Biomedical Reports



ISSN 2049-9434
eISSN 2049-9442


An international journal devoted to Biomedical Research

VOLUME 17, NUMBER 5, NOVEMBER 2022



[Oncology Letters](#)[International Journal of Oncology](#)[Molecular and Clinical Oncology](#)[Experimental and Therapeutic Medicine](#)[International Journal of Molecular Medicine](#)[Biomedical Reports](#)[Oncology Reports](#)[Molecular Medicine Reports](#)[World Academy of Sciences Journal](#)[International Journal of Functional Nutrition](#)[International Journal of Epigenetics](#)[Medicine International](#)

Biomedical Reports

[Journal Home](#)[Current Issue](#)[Forthcoming Issue](#)[Special Issues](#)[Most Read](#)[Most Cited \[Dimensions\]](#)[Most Cited \[CrossRef\]](#)[Social Media](#)[Archive](#)

Biomedical Reports

If you are interested in becoming an Editorial Board Member for Spandidos Publications and you meet the criteria [here](#) please click the link below. You can click [here](#) to submit your application.

Editor in Chief:

DEMETRIOS A. SPANDIDOS,

BSc, PhD, FRCPath, DSc, FRSH, FASA, MAE

CV - [PUBLICATIONS - THE CANCER STORY - SPANDIDOS LAB](#)

Professor Emeritus, Medical School, University of Crete, Heraklion, Greece

Spandidos Publications, Greece

Deputy Editors:

ATHANASIA SPANDIDOS, BSc (Hons), PhD, **CV**

Spandidos Publications, Greece

NIKIFOROS A. SPANDIDOS, BSc (Hons), MSc, PhD

Spandidos Publications, United Kingdom

Senior Executive Editor:

VASILIS P. ANDROUTSOPOULOS, BSc, MSc, PhD

Spandidos Publications, Greece

Editorial Board:

Arturo Aguilar-Rojas

**Arturo Aguilar-Rojas,** Mexican Institute of Social Security (IMSS), Mexico**Ahmed Al-Dwairi** **November-2022****Volume 17 Issue 5**

Print ISSN: 2049-9434

Online ISSN: 2049-9442

[Sign up for eToc alerts](#)[Recommend to Library](#)[Full Size Image](#)

Journal Metrics

Impact Factor:
Awaiting in 2023CiteScore: **3.9**CiteScore Rank: **Q2:**
#20/74Pharmacology,
Toxicology and
PharmaceuticsSource Normalized
Impact per Paper
(SNIP): **0.742**SCImago Journal
Rank (SJR): **0.488****Tweets from
@BiomedicalR
epo1** **Biomedical Reports ...**
Sp...
Jun 28

Information

[Online Submission](#)[Information for Authors](#)[Language Editing](#)[Information for Reviewers](#)[Editorial Policies](#)[Editorial Board](#)[Join Editorial Board](#)[Aims and Scope](#)[Abstracting and Indexing](#)[Bibliographic Information](#)[Information for Librarians](#)[Information for Advertisers](#)[Reprints and permissions](#)[Contact the Editor](#)

[General Information](#)

[About Spandidos](#)

[Conferences](#)

[Job](#)

[Opportunities](#)

[Contact](#)

[Terms and Conditions](#)



Ahmed Al-Dwairi, Jordan University of Science and Technology, Jordan

Akira Andoh



Akira Andoh, Shiga University of Medical Science, Japan

[Dimiter B. Avtanski](#)



Dimiter B. Avtanski, Northwell Health, New York, United States

[Shigeki Bamba](#)



Shigeki Bamba, Shiga University of Medical Science, Japan

[Aditi Banerjee](#)



Aditi Banerjee, University of Maryland School of Medicine, United States

Jose Alexandre M. Barbuto



Jose Alexandre M. Barbuto, ICB-University of Sao Paulo, Brazil

Mohamed Boudjelal



Mohamed Boudjelal, KAIMRC-Ministry National Guard Health Affairs, Saudi Arabia

Timo Burster



Timo Burster, Nazarbayev University, Kazakhstan

[Tongjian Cai](#)



Tongjian Cai, Third Military Medical University, China

Saverio Candido

· JUN 20

The overall trend in Impact Factors for Spandidos Publications Journals featured in JCR over the course of the last 11 years is shown in the attached graphic.

2 1

[Biomedical Reports ...](#)
Sp...
· Jun 28

The new Impact Factors for the Spandidos Publications journals that are indexed in JCR are shown in tabulated form in the attached graphic.

[Biomedical Reports ...](#)
Sp...
· Jun 28

Following the release of Journal Citation Reports 2022 (published by Clarivate), we are pleased to announce some significant increases in the Impact Factors (IFs) for our Journals. All listed Journals have seen their IFs increase. More information to come in the following thread!

2

[Biomedical Reports ...](#)
Sp...
· Jun 13

We are pleased to announce that all of our journals have increased in terms of their scores and rankings following the recent release of 'Citescore 2021'. Here is a summary all the updated information at a glance in a graphic:

Saverio Candido

**Saverio Candido**, University of Catania, ItalyFederico Castro-Muñozledo**Federico Castro-Muñozledo**, Center for Research and Advanced Studies (Cinvestav), MexicoHyuk-Jin Cha**Hyuk-Jin Cha**, Seoul National University, Republic of KoreaMichael Chan**Michael Chan**, National Chung Cheng University, Taiwan

Tak Hang Chan

**Tak Hang Chan**, McGill University, Canada

Anil Kumar Chauhan

**Anil Kumar Chauhan**, The Ohio State University, United States

Jiwang Chen

**Jiwang Chen**, University of Illinois at Chicago, United StatesKok-Yon Chin**Kok-Yon Chin**, Universiti Kebangsaan Malaysia Medical Centre, Malaysia

Shiow-Her Chiou

**Shiow-Her Chiou**, National Chung Hsing University, Taiwan

Biomedical Reports ...

Sp...
· Jun 13Replying to
[@SpandidosP](#)

Biomedical Reports: latest CiteScore, 3.9; in Quartile Q2 [cf. 2.9, Q2 in 2020].

[View more on Twitter](#)

Follow

[Yung Hyun Choi](#) 



Yung Hyun Choi, Dongeui University College of Oriental Medicine, Republic of Korea

[James C.L. Chow](#) 



James C.L. Chow, University of Toronto, Canada

[Kuan-Chih Chow](#)



Kuan-Chih Chow, National Chung Hsing University, Taiwan

[Marinella Coco](#)




Marinella Coco, University of Catania, Italy

[Giuseppina De Petro](#) 




Giuseppina De Petro, University of Brescia, Italy

[Haiteng Deng](#) 



Haiteng Deng, Tsinghua University, China

[Linhong Deng](#) 




Linhong Deng, Changzhou University, China

[Qingping Dou](#) 




Qingping Dou, Barbara Ann Karmanos Cancer Institute of Wayne State University, United States

[Tomas J. Ekström](#) 



Tomas J. Ekström, Karolinska Institutet, Sweden

[Magdy El-Salhy](#) 



Magdy El-Salhy, Stord Helse-Fonna Hospital, Norway

Toshihiko Ezashi



Toshihiko Ezashi, University of Missouri-Columbia, United States

Angela Scevola Faga




Angela Scevola Faga, University of Pavia, Italy

[Concettina Fenga](#) 



Concettina Fenga, University of Messina, Italy

[Esteban C. Gabazza](#) 




Esteban C. Gabazza, Mie University, Japan

Wei Gao



Wei Gao, Nanjing Medical University, China

[Domenico Grieco](#) 



Domenico Grieco, University of Naples "Federico II", Italy

Irina Groisman



Irina Groisman, Curie Institute, France

Xiaoxiang Guan



Xiaoxiang Guan, Jinling Hospital, Nanjing University School of Medicine, China

[Feng He](#)



Feng He, University of California, San Diego, United States

[Gu He](#)



Gu He, Sichuan University, China

[Abdelmonem Hegazy](#)



Abdelmonem Hegazy, Faculty of Medicine, Zagazig University, Egypt

[Yoshitaka Hosokawa](#)



Yoshitaka Hosokawa, Tokushima University, Japan

[Gennaro Ilardi](#)



Gennaro Ilardi, University of Naples "Federico II", Italy

[Toru Ishikawa](#)



Toru Ishikawa, Saiseikai Niigata Hospital, Japan

[Hajime Isomoto](#)



Hajime Isomoto, Tottori University, Japan

[Athanasios Jamurtas](#)



Athanasios Jamurtas, University of Thessaly, Greece

[Byeong-Churl Jang](#)



Byeong-Churl Jang, Keimyung University School of Medicine, Republic of Korea



[Jerzy Jankun](#)



Jerzy Jankun, The University of Toledo, United States

[Thanasekaran Jayakumar](#)



Thanasekaran Jayakumar, Taipei Medical University, Taiwan

Moon-Jin Jeong



Moon-Jin Jeong, Chosun University School of Dentistry, Republic of Korea

[Wen Guo Jiang](#)



Wen Guo Jiang, Cardiff University School of Medicine, United Kingdom

[Bernd Kaina](#)



Bernd Kaina, University Medical Center Mainz, Germany

Makoto Kammori



Makoto Kammori, Niizashiki Central General Hospital, Japan

Hideo Kaneko



Hideo Kaneko, Gifu Prefectural General Medical Center, Japan

[Jaeku Kang](#)



Jaeku Kang, Konyang University, Republic of Korea

[Theodoros Kantidakis](#)



Theodoros Kantidakis, Aston University, United Kingdom



Satoru Kase



Satoru Kase, Hokkaido University Graduate School of Medicine, Japan

Ko-ichi Kawahara



Ko-ichi Kawahara, Osaka Institute of Technology, Japan

Tomoyuki Kawase



Tomoyuki Kawase, Niigata University, Japan

Sun Hoe Koo



Sun Hoe Koo, Chungnam National University College of Medicine, Republic of Korea

Yoshimasa Kosaka



Yoshimasa Kosaka, Saitama Medical University International Medical Center, Japan

Dimitrios Kouretas



Dimitrios Kouretas, University of Thessaly, Greece

Dinesh Kumar



Dinesh Kumar, Centre of Biomedical Research, Lucknow, India, India

Nitesh Kumar



Nitesh Kumar, Manipal Academy of Higher Education, India

Chan-Yen Kuo





Chan-Yen Kuo, Taipei Tzu Chi Hospital, Taiwan

Ashakumary Lakshmikuttyamma



Ashakumary Lakshmikuttyamma, Thomas Jefferson University, United States

Cord Langner



Cord Langner, Graz Medical University, Austria

Dong-Sung Lee



Dong-Sung Lee, Chosun University, Republic of Korea

Jung Sup Lee



Jung Sup Lee, Chosun University, Republic of Korea

Young Han Lee



Young Han Lee, Konkuk University, Republic of Korea

Chanvit Leelayuwat



Chanvit Leelayuwat, Khon Kaen University, Thailand

Zhiming Li



Zhiming Li, Columbia University Irving Medical Center, United States

Yoongho Lim



Yoongho Lim, Konkuk University, Republic of Korea

Sheng-Zhang Lin



Sheng-Zhang Lin, Zhejiang University School of Medicine, China

Kai Liu



Kai Liu, Shanghai Jiao Tong University School of Medicine, China

Xuele Ma



Xuele Ma, West China Hospital, China

Andrea Marino



Andrea Marino, Department of Clinical and experimental medicine,
University of Catania, Catania, Italy, Italy

Gabriella Martino



Gabriella Martino, University of Messina, Italy

Marwa Matboli



Marwa Matboli, Modern University for Technology and Information, Egypt

Hiroshi Matsushita



Hiroshi Matsushita, Aichi Medical University, Japan

Bradley McConnell



Bradley McConnell, University of Houston, United States

Byung-Moo Min



Byung-Moo Min, Seoul National University School of Dentistry, Republic of
Korea

Yoshiyuki Mizushina



Yoshiyuki Mizushina, Shinshu University, Japan

Mathias Montenarh



Mathias Montenarh, Saarland University, Germany

Hiroshi Morimatsu



Hiroshi Morimatsu, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

Tomiyasu Murata



Tomiyasu Murata, Meijo University, Japan

Yoriko Murata



Yoriko Murata, Kochi Medical School, Japan

Maria Aparecida Nagai



Maria Aparecida Nagai, University of Sao Paulo, Brazil

Yumiko Nagao



Yumiko Nagao, Juntendo University School of Medicine, Japan

Isao Nagaoka



Isao Nagaoka, Juntendo University, Graduate School of Medicine, Japan

Tsutomu Namikawa



Tsutomu Namikawa, Kochi Medical School, Japan

[Nance Beyer Nardi](#)**Nance Beyer Nardi**, Lutheran University of Brazil, Brazil[Daniel Neureiter](#)**Daniel Neureiter**, University Institute of Pathology, Paracelsus Medical Private University, Austria[Giovanni Nicoletti](#)**Giovanni Nicoletti**, University of Pavia, Italy[Giuseppe Nunnari](#)**Giuseppe Nunnari**, University of Messina, Italy[Yusuke Oji](#)**Yusuke Oji**, Osaka University Graduate School of Medicine, Japan

Chaehwa Park

**Chaehwa Park**, Sungkyunkwan University, Republic of Korea

Joonhong Park

**Joonhong Park**, Jeonbuk National University Medical School and Hospital, Republic of Korea[Gianni Pes](#)**Gianni Pes**, University of Sassari, Italy

Andreas A. Prachalias

**Andreas A. Prachalias**, King's College Hospital, United Kingdom

[Mohd Salim Reshi](#) 




Mohd Salim Reshi, Baba Ghulam Shah Badshah University, India

[Daniel Araki Ribeiro](#) 



Daniel Araki Ribeiro, Federal University of Sao Paulo, Brazil

[James Alexander Ross](#) 




James Alexander Ross, University of Edinburgh, United Kingdom

Eiji Sakai




Eiji Sakai, Yokohama City University School of Medicine, Japan

[Hiroaki Satoh](#) 



Hiroaki Satoh, University of Tsukuba, Japan

[Jianliang Shen](#) 



Jianliang Shen, Wenzhou Medical University, China

Hideo Shigeishi



Hideo Shigeishi, Hiroshima University, Japan

Noriaki Shimokawa



Noriaki Shimokawa, Takasaki University of Health and Welfare, Japan

Motoyuki Shimonaka



Motoyuki Shimonaka, Tokyo University of Science, Japan



[Tatsuo Shimura](#)



Tatsuo Shimura, Maki Hospital, Japan

[Katsuya Shiraki](#)



Katsuya Shiraki, Mie General Medical Center, Japan

[Yoshio Suzuki](#)



Yoshio Suzuki, Juntendo University, Japan

[Junko Takahashi](#)



Junko Takahashi, National Institute of Advanced Industrial Science and Technology (AIST), Japan

[Shinichiro Takahashi](#)



Shinichiro Takahashi, Tohoku Medical and Pharmaceutical University, Japan

[Takashi Takeda](#)



Takashi Takeda, Keio University School of Medicine, Japan

[Kenneth Kin Wah To](#)



Kenneth Kin Wah To, The Chinese University of Hong Kong, China

[Gary Tse](#)



Gary Tse, Tianjin Medical University, China

[Ikuyo Tsukamoto](#)



Ikuyo Tsukamoto, Nara Women's University, Japan



Aria Tzika



Aria Tzika, Massachusetts General Hospital and Harvard Medical School, United States

[Ioannis S. Vizirianakis](#)



Ioannis S. Vizirianakis, Aristotle University of Thessaloniki, Greece

Ioannis A. Voutsadakis



Ioannis A. Voutsadakis, Northern Ontario School of Medicine, Canada

[Junpeng Wang](#)



Junpeng Wang, Henan University, China

[Ping Wang](#)



Ping Wang, The Feinstein Institute for Medical Research, United States

Mervyn Neale Weitzmann



Mervyn Neale Weitzmann, Emory University, United States

[Adrian Whitehouse](#)



Adrian Whitehouse, University of Leeds, United Kingdom

[Ai-Min Wu](#)



Ai-Min Wu, Wenzhou Medical University, China

Joseph M. Wu

**Joseph M. Wu**, New York Medical College, United States

Jian-hui Xiao

**Jian-hui Xiao**, Zunyi Medical University, ChinaKyosuke Yamanishi**Kyosuke Yamanishi**, Hyogo College of Medicine, JapanWoong Mo Yang**Woong Mo Yang**, Kyung Hee University, Republic of Korea

Yi-Qing Yang

**Yi-Qing Yang**, Fudan University, ChinaHiroyuki Yoshida**Hiroyuki Yoshida**, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, JapanJinlu Yu**Jinlu Yu**, Jilin University, ChinaYung-Luen Yu**Yung-Luen Yu**, China Medical University, TaiwanChengfei Zhang**Chengfei Zhang**, The University of Hong Kong, ChinaFaming Zhang



Faming Zhang, Nanjing Medical University, China

[Yunfeng Zhao](#)



Yunfeng Zhao, LSU Health Sciences Center, United States

[Dali Zheng](#)



Dali Zheng, Fujian Medical University, China

[Wang Zheng](#)



Wang Zheng, Boston Children's Hospital, United States

[Mingyuan Zou](#)



Mingyuan Zou, Southeast University, China

[Marlena Zyśk](#)



Marlena Zyśk, Medical University of Gdansk, Poland

A 5-year evaluation of chemoprophylactic treatment in elementary school children with subclinical leprosy

LINDA ASTARI¹⁻⁴, NASTITI INTAN PERMATA SARI⁵, KUSNARTEDJO NANANG⁶, EDY CAHYONO⁶,
NANNY HERWANTO^{2,3}, MUHAMMAD YULIANTO LISTIAWAN^{2,3}, DINAR ADRIATY⁴,
ISWAHYUDI ISWAHYUDI⁴, RATNA WAHYUNI^{4,7}, MEDHI DENISA ALINDA^{2,3},
BAGUS HARYO KUSUMAPUTRA^{2,3}, REGITA INDIRA AGUSNI^{2,3}, INDROPO AGUSNI²⁻⁴,
SHINZO IZUMI⁴ and CITA ROSITA SIGIT PRAKOWESWA²⁻⁴

¹Doctoral Program of Medical Science; ²Department of Dermatovenereology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java 60131; ³Dr. Soetomo General Academic Hospital, Surabaya, East Java 60285;

⁴Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java 60115;

⁵Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Pertaahanan, Bogor, West Java 16810;

⁶Sumberglagah Leprosy Hospital, Mojokerto, East Java 67152;

⁷Department of Health, Faculty of Vocational Studies, Universitas Airlangga, Surabaya East Java 60286, Indonesia

Received March 16, 2020; Accepted June 2, 2021

DOI: 10.3892/br.2021.1464

Abstract. Subclinical leprosy is an infectious disease in which the immune system remains infected with *Mycobacterium leprae* (*M. leprae*). The progress of subclinical leprosy to clinical cases within 1 year of infection is 1.5%, with an increase to 6% in the following 4 years. Rifampicin is frequently used for prevention of leprosy, and clarithromycin has a bactericidal effect on *M. leprae*. Thus, the combination of both is expected to improve disease control in patients with subclinical leprosy. The aim of the present study was to evaluate the efficacy of a chemoprophylactic treatment involving rifampicin and clarithromycin against subclinical leprosy in elementary school children from endemic areas of East Java over a 5-year period. The study was performed between 2011 and 2015. Samples were collected from 2,548 healthy elementary school children in Nguling (Pasuruan) and Raas (Sumenep), and analysed using ELISA for anti-PGL (phenolic glycolipid)-1 IgM antibodies. Children who were seropositive for anti-PGL-1 IgM antibodies received a chemoprophylactic regimen consisting of rifampicin (300 mg/day) and clarithromycin (250 mg/day) daily for the initial 10 days, followed by the same regimen every 2 weeks for 3 months. Clinical and serological evaluations were performed annually for 5 years. Amongst the 2,548 healthy elementary school children,

200 were seropositive. The anti-PGL-1 IgM antibody levels significantly decreased between 2011 and 2015 in Nguling (from 1,066.7 to 137.4 U/ml) and Raas (from 773.1 to 563.4 U/ml), the levels decreased every year. In addition, the proportion of patients with decreased anti-PGL-1 IgM antibody levels was consistently higher than patients with increased anti-PGL-1 IgM antibody levels in all periods, except during 2013-2014, in Nguling and Raas. Chemoprophylactic treatment involving rifampicin and clarithromycin may thus be effective against subclinical leprosy amongst elementary school children.

Introduction

In 2015, Indonesia was amongst the three countries (along with India and Brazil) which reported >10,000 new leprosy cases, contributing to 8% of new cases globally. Amongst all new patients with leprosy in Indonesia, 10% had already progressed to disability on diagnosis, and 11% were children (1). Leprosy in children is quite common in endemic countries. Moreover, 20-30% of patients with new cases exhibit neuritis and some are diagnosed with disability (2). The younger patients (<15 years) show active circulation and transmission of *Mycobacterium leprae* (*M. leprae*) within the community, thus reflecting inefficiency in the national health system (3-5). With regard to leprosy in children, the most important matter is the prevention of disability and deformities by early detection and improved treatment of leprosy in leprosy endemic areas (6). Leprosy in children, particularly subclinical leprosy, may occur as currently, treatments are focused only on clinical leprosy, and subclinical leprosy is not a focus, even though patients with subclinical leprosy are sources of further infection.

A healthy individual exhibiting a sufficient immune response will typically attack an *M. leprae* infection; however, an individual with a compromised immune system may not be able to

Correspondence to: Professor Cita Rosita Sigit Prakoeswa, Department of Dermatovenereology, Faculty of Medicine, Universitas Airlangga, Jl. Prof. Dr. Moestopo no. 47, Surabaya, East Java 60131, Indonesia
E-mail: cita-rosita@fk.unair.ac.id

Key words: *Mycobacterium leprae*, subclinical leprosy, clinical leprosy, clarithromycin, infectious disease

find of the *M. leprae* infection appropriately, and this condition is considered subclinical leprosy (7). Subclinical leprosy can develop into clinical leprosy within 2-10 years, depending on the individual's immune status (8,9). In 2008, the International Leprosy Congress (Hyderabad) showed that 1.5% of subclinical leprosy cases progress to clinical leprosy cases within 1 year, which increases to 6% in the following 4 years (5,10,11). Thus, it is crucial to prevent the progression of subclinical leprosy to clinical leprosy, as the latter is more infectious and potentially more debilitating for the patient (5,10,11). Using sensitive and specific screening tests is important to control transmission of leprosy. Serological tests have become the most common approach to detect subclinical infection (5,10,11). PGL-1, a specific *M. leprae* cell wall antigen, is a popular antigen assessed for using antibodies, as its presence can be detected in the serum. Detection using these antibodies can be used for diagnosis, prediction of recurrence and identification of the risk of spreading the disease amongst individuals or within the community (5,10,11). A meta-analysis by Penna *et al* (12) concluded that the risk of spreading from patients with clinical leprosy is ~3X higher amongst patients positive for anti-PGL-1 antibodies than those who were negative for these antibodies. Furthermore, it has been shown that leprosy contacts (13,14) and population (15) in an leprosy endemic area, with IgM anti-PGL-1 seropositivity have a 6-fold higher relative risk of becoming ill from leprosy in the 6-10 years of follow-up.

Various types of chemoprophylactic approaches have shown favourable results for prevention of leprosy infection or subclinical leprosy. In a previous study, intermittent dapsone administration for 2 years and intermittent acedapsone administration for 7 months reduced the risk of leprosy by 60 and 49%, respectively (16). The single-dose rifampicin (SDR) chemoprophylactic regimen is currently being used in Indonesia, as well as in India, as well as several other ASEAN countries (17). However, this regimen has been shown to reduce the incidence of leprosy by only 57% (18). The efficacy of this regimen is more distinguished in distant contacts than in close contacts of index patients and may be associated with the bacillary load, which is supposedly higher in close contacts than in infrequent contacts (19,20). Furthermore, studies have shown that SDR is effective for the prevention of leprosy only in those who receive a regimen; as such, SDR should be ideally administered to entire communities for it to exert an effect at the community level (19,21). Therefore, early detection of index cases, increased coverage of SDR post-exposure prophylaxis (PEP), detection of subclinical leprosy followed by direct PEP and enhancement of the PEP regimen (PEP⁺⁺ regimen) are required to improve prevention programs. The improved regimen is expected to be sufficiently effective for the treatment of patients with subclinical leprosy who possess a high bacillary load.

Clarithromycin exhibits a bactericidal effect on *M. leprae* and has an important role in the treatment of rifampicin-resistant leprosy (22-24). The pharmacokinetics are promising given its ability to penetrate well into macrophages and leukocytes (4,25), which are the targets of *M. leprae* (5). Thus, a combination of clarithromycin and rifampicin may facilitate improved disease control in patients with subclinical leprosy.

The aim of the present study was to evaluate the efficacy of a chemoprophylactic treatment involving rifampicin and clarithromycin against subclinical leprosy in elementary school

children from endemic areas in East Java (Indonesia) over a 5-year period.

Materials and methods

Criteria. The primary criteria for the present study were as follows: High endemicity (≥ 250 new cases per year in the last 3 years), epidemiological data available for at least the last 10 years, population not highly mobile, good collaboration with government health services, willingness to integrate prophylactic treatment involving leprosy health services, high logistical feasibility and good health infrastructure (including adequate leprosy services and contact screening).

Patients. The present study was performed annually between 2011 and 2015. Samples were collected from 2,548 healthy elementary school students who were not contacts of patients with leprosy. The students were recruited from several elementary schools in one area, but the school grades differed according to age. All students obtained consent from their parents to participate in the present study, and signed an informed consent form that clearly stated the purpose of the research, the method of sample collection, and the lack of risk from medical procedures. They also received an agreement form and resignation form. The present study was approved by the Ethical Committee in Health Research Unit of Dr. Soetomo General Hospital Surabaya, Indonesia (approval no. 30-511/H3.13/PPd/2012).

The recruited cohort consisted of 39 males and 59 females, and the age ranged from 7-14 years old. The regions from which patients were recruited were located in East Java, Indonesia; specifically, Nguling (Pasuruan) and Raas (Sumenep). Collection of samples in this study was performed by home visits during the 5 years of observation, and was completed using portable equipment. Peripheral blood samples were collected from one finger following disinfection. The collection of the blood used a capillary pipette; 100 μ l was collected, and this was then placed on a filter paper (Whatman, PLC; GE Healthcare Life Sciences; cat. no. 1442 110) until dry to avoid contaminants, such as fungi (26).

Serological test. The samples were analysed using indirect ELISA using anti-PGL-1 (NTP-BSA; cat. no. Nara XVII-48) according to the manufacturer's protocol for anti-PGL-1 IgM antibodies (27). A level of 605 U/ml or above was considered to indicate seropositivity. Antibody titres were classified as follows: +1, 605-1,000 U/ml; +2, 1,001-2,000 U/ml; +3, 2,001-3,000 U/ml; and +4, >3,000 U/ml.

Treatment regimens. Participants who were seropositive for anti-PGL-1 IgM antibodies received a chemoprophylactic regimen involving rifampicin (300 mg/day) and clarithromycin (250 mg/day) every day for the initial 10 days and then received the same regimen every 2 weeks for 3 months. Evaluation of clinical and serological positivity was performed every year for 5 years (28,29).

Data presentation. Descriptive analysis was used for the results of the present study. Data presentation was performed

Table I. Mean of anti-PGL-1 IgM antibody levels in the children recruited from Nguling and Raas between 2011 and 2015.

Year	Mean	
	Nguling	Raas
2011	1066,71875	773,123077
2012	685,15625	560,923077
2013	450,59375	281,276923
2014	599	411,353846
2015	137,4375	5,634

using Microsoft Excel version 16.42 (Microsoft Corporation), and included frequency (raw data) and mean of the anti-PGL-1 levels (Table I).

Results

Among the 2,548 healthy elementary school children, 200 were seropositive (79 from Nguling and 121 from Raas). During the 5 years observation period only 98 (49%) seropositive children had complete data; Nguling 41.8% (33/79) and Raas 53.7% (65/121). In addition, certain children were lost after >1 follow-up visit and could not be contacted, or their home was in a difficult to reach location. Other children moved with their parents to another city. Overall, the prophylactic drugs were well tolerated, and few side effects associated with the drugs were reported. Notably, after the 5-years of observation, there were no children with subclinical leprosy that exhibited progression to clinical leprosy. The average of anti-PGL-1 IgM antibody levels decreased significantly between 2011 and 2015 in Nguling and Raas (from 1,066.72 to 137.44 U/ml and from 773.12 to 563.40 U/ml, respectively). Using the antibody titres classification, the results showed that Nguling was seropositive +2 and Raas had seropositive +1 overall in 2011.

The proportion of patients with decreased levels of anti-PGL-1 IgM antibody in Nguling and Raas was consistently higher than patients with increased levels of anti-PGL-1 IgM antibody in all periods, except during 2013-2014.

Discussion

Elimination of viable *M. leprae* in a population is a crucial step to reducing transmission. To be successfully eliminated, it is important to consider that viable *M. leprae* are present not only in individuals with clinical leprosy, but also in those who have subclinical leprosy. Unfortunately, its presence in individuals with subclinical leprosy is often undetected, as the current treatment approaches tend to focus on individuals with clinical leprosy. This phenomenon may explain why it has proven difficult to completely eradicate leprosy (16).

The present study evaluated the efficacy of a chemoprophylactic treatment regimen consisting of rifampicin and clarithromycin for 5 years. Early detection of subclinical leprosy can be performed using capillary blood and ELISA to determine the titre of anti-PGL-1 IgM antibody (21). The procedure was relatively easy, applicable and convenient for

the participants. The samples can be dried and stored for a relatively long time prior to analysis or referral (21). Therefore, this procedure may be suitable to support the sustainability of early detection and prophylactic programmes. However, a previous study showed that anti-PGL-1 antibody was not an efficient predictor of contacts that may develop leprosy in endemic areas, and suggested that more specific biomarkers are required for early detection of leprosy (30). Another study showed that the sensitivity of anti-PGL-1 antibody for early detection of clinical leprosy was <50%, although the specificity was 80% (3). Nevertheless, as mentioned in a study by Barreto *et al* (3), several reports have found higher levels of anti-PGL-1 antibodies in children and young adults compared with older adults (3). Moreover, this previous study reported higher levels of anti-PGL-1 antibodies in children living in rural areas (considered to be busy areas facing food shortages) than in children living in high-income areas.

Previous studies on leprosy contacts (13,14) or on blood donors representing the population of an endemic area in south eastern Brazil (15) found a 6-fold higher relative risk of illness in individuals who were IgM anti-PGL-1 seropositive. The present study showed a promising result of a decrease in the average levels of anti-PGL-1 IgM antibody every year for 5 years with prophylactic treatment. These results contradict the findings of Moet *et al* (18) who showed that chemoprophylactic treatment involving SDR had a protective effect only for the initial 2 years. In their initial 2-year follow-up, rifampicin prevented leprosy, particularly in individuals aged 10-14 and 20-29 years old. The difference in results may be related to the addition of clarithromycin. The present study used children who were not contacts of patients with leprosy, and the age range of the recruited cohort was 7-14 years old, all from an endemic area of leprosy. However, a previous study by Ghidar *et al* (31) showed that the addition of clarithromycin to a single-lesion therapy regimen did not increase cure rates (31). Nevertheless, at the 2-year follow-up, relapse rates were lower in the patients who received clarithromycin compared with those who did not; however, the difference was not significant. *M. leprae* is an obligate intracellular pathogen, which attacks macrophages for replication. A previous study on *M. leprae*-infected macrophages showed that invasion interferes with the activation of the cell-mediated immune responses that are required to attack *M. leprae* (32). Thus, the bactericidal activity of clarithromycin in macrophages can help improve the host's immune response, to reduce the amount of viable *M. leprae* and possibility of clinical leprosy.

Previous studies have shown that prophylactic treatment is very effective when given to the entire population, rather than only close contacts of patients with leprosy (19,20). This may be related to the presence of viable *M. leprae* in undetected individuals or in those from untreated areas (20). However, favourable results were obtained in the present study, even though prophylactic treatment was only administered in a population of elementary school children.

A previous study in families of patients with leprosy treated with a multidrug treatment (MDT) regimen showed that several parents were not sufficiently educated. The drugs in the MDT regimen are usually taken by children, and it has been reported certain children are administered the incorrect

drugs. Therefore, education of chemoprophylactic regimens for parents and teachers should be integrated into treatment programmes to promote a positive attitude and supportive environment for children (33).

The present study has some limitations. Specific doses of rifampicin and clarithromycin according to age and body weight were not used. The dosage used was based on the age range, as this method is easy but still valid when used in home visits. Treatment with specific doses may help optimize therapy and minimize side effects (28,29).

In conclusion, the prophylactic treatment of children with subclinical leprosy showed good results over the 5 years evaluation period, and the prophylactic regimen used was well tolerated. After the 5-years of observation, there were no children with subclinical leprosy that exhibited progression to clinical leprosy, thus this regimen should be considered as a future prophylactic treatment for subclinical leprosy, particularly in children.

Acknowledgements

We would like to thank to Mr Sumarsono (Bachelor of Public Health) for assisting with the co-ordination of the present study.

Funding

The present study was funded by the East Java Provincial Government (grant no. 1.02-0106-22-005-5-2).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

LA performed the analysis, and wrote and revised the manuscript based on suggestions from the other authors. NIPS contributed to study design, proofreading and manuscript revision. KN, EC, NH, MYL, DA, II, RW, MDA, BHK and RIA collected the samples and performed the measurements. IA, SI and CRSP contributed to study design, manuscript drafting and revision for intellectual content. All authors have read and approved the final manuscript. All authors confirm the authenticity of all the raw data.

Ethics approval and consent to participate

All students obtained consent from their parents to participate in the present study, and signed an informed consent form that clearly stated the purpose of the research, the method of sample collection, and the lack of risk from medical procedures. They also received an agreement form and resignation form. The present study was approved by the Ethical Committee in Health Research Unit of Dr. Soetomo General Hospital Surabaya, Indonesia (approval no. 30-511/H3.13/PPd/2012).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. WHO: Weekly Epidemiological Report. WHO 91: 405-420, 2016.
2. Butlin CR and Saunderson P: Children with leprosy. *Lepr Rev* 85: 69-73, 2014.
3. Barreto JG, Guimarães Lde S, Frade MA, Rosa PS and Salgado CG: High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon region. *Mem Inst Oswaldo Cruz* 107 (Suppl 1): S60-S67, 2012.
4. Oliveira MBB and Diniz LM: Leprosy among children under 15 years of age: Literature review. *An Bras Dermatol* 91: 196-203, 2016.
5. Lourenco DSD, Campelo TA, Cruz GA, De Almeida PC, Sa Goncalves HD, Pontes MADA, Lima LNGC and Frota CC: Detection of subclinical *Mycobacterium leprae* infection in children, contacts of leprosy cases, Fortaleza-Ceara', Brazil. *Lepr Rev* 88: 184-196, 2017.
6. Adriaty D, Sp CR, Iswahyudi, Wahyuni R, Agusni I and Izumi S: Leprosy transmission in endemic and non-endemic areas based on the profile of antibody response of PGL-1 and PCR detection of *Mycobacterium leprae* DNA from nasal swab among healthy children of East Java, Indonesia. *Infec Dis Rep* 12 (Suppl 1): S8748, 2020.
7. Fine PE: Leprosy: The epidemiology of a slow bacterium. *Epidemiol Rev* 4: 161-188, 1982.
8. Van Beers SM, de Wit MY and Klatser PR: The epidemiology of *Mycobacterium leprae*: Recent insight. *FEMS Microbiol Lett* 136: 221-230, 1996.
9. Hooij AV and Geluk A: Immunodiagnostic for leprosy. In: *International Textbook of Leprosy*. Scollard D and Gillis T (eds). American Leprosy Missions, pp. 2-3, Leiden, The Netherlands, 2016.
10. Moura RS, Calado KL, Oliveira ML and Bühner-Sékula S: Leprosy serology using PGL-1: A systematic review. *Rev Soc Bras Med Trop* 41 (Suppl 2): S11-S18, 2008.
11. Araújo S, Lobato J, Reis Éde M, Souza DO, Gonçalves MA, Costa AV, Goulart LR and Goulart IM: Unveiling healthy carriers and subclinical infections among household contacts of leprosy patients who play potential roles in the disease chain of transmission. *Mem Inst Oswaldo Cruz* 107 (Suppl 1): S55-S59, 2012.
12. Penna ML, Penna GO, Iglesias PC, Natal S and Rodrigues LC: Anti-PGL-1 positivity as a risk marker for the development of leprosy among contacts of leprosy cases: Systematic review and meta-analysis. *PLoS Negl Trop Dis* 10: e0004703, 2016.
13. Araujo S, Rezende MM, Sousa DC, Rosa MR, Santos DC, Goulart LR and Goulart IMB: Risk-benefit assessment of Bacillus Calmette-Guérin vaccination, anti-phenolic glycolipid I serology, and Mitsuda test response: 10-year follow-up of household contacts of leprosy patients. *Rev Soc Bras Med Trop* 48: 739-745, 2015.
14. Araújo S, Freitas LO, Goulart LR and Goulart IMB: Molecular evidence for the aerial route of infection of *Mycobacterium leprae* and the role of asymptomatic carriers in the persistence of leprosy. *Clin Infect Dis* 63: 1412-1420, 2016.
15. Goulart IM, Araújo S, Filho AB, de Paiva PH and Goulart LR: Asymptomatic leprosy infection among blood donors may predict disease development and suggests a potential mode of transmission. *J Clin Microbiol* 53: 3345-3348, 2015.
16. Reveiz L, Buendía JA and Téllez D: Chemoprophylaxis in contacts of patients with leprosy: Systematic review and meta-analysis. *Rev Panam Salud Publica* 26: 341-349, 2009.
17. Barth-Jaeggi T, Steinmann P, Mieras L, van Brakel W, Richardus JH, Tiwari A, Bratschi M, Cavaliero A, Vander Plaetse B, Mirza F, *et al.*: Leprosy Post-Exposure Prophylaxis (LPEP) programme: Study protocol for evaluating the feasibility and impact on case detection rates of contact tracing and single dose rifampicin. *BMJ Open* 6: e013633, 2016.
18. Moet FJ, Pahan D, Oskam L and Richardus JH: COLEP Study Group: Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: Cluster randomised controlled trial. *BMJ* 336: 761-764, 2008.
19. Bakker MI, Hatta M, Kwenang A, Van Benthem BH, Van Beers SM, Klatser PR and Oskam L: Prevention of leprosy using rifampicin as chemoprophylaxis. *Am J Trop Med Hyg* 72: 443-448, 2005.

20. Smith WC and Aerts A: Role of contact tracing and prevention strategies in the interruption of leprosy transmission. *Lepr Rev* 85: 2-17, 2014.
21. Feenstra SG, Pahan D, Moet FJ, Oskam L and Richardus JH: Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. *Lepr Rev* 83: 292-304, 2012.
22. Ji B, Jamet P, Perani EG, Bobin P and Grosset JH: Powerful bactericidal activities of clarithromycin and minocycline against *Mycobacterium leprae* in lepromatous leprosy. *J Infect Dis* 168: 188-190, 1993.
23. Walker LL, VanLandingham RM and Shinnick TM: Clarithromycin is bactericidal against strains of *Mycobacterium leprae* resistant and susceptible to dapsone and rifampin. *Int J Lepr Other Mycobact Dis* 61: 59-65, 1993.
24. Lazo-Porrás M, Prutsky GJ, Barrionuevo P, Tapia JC, Ugarte-Gil C, Ponce OJ, Acuña-Villaorduña A, Domecq JP, De la Cruz-Luque C, Prokop LJ and Málaga G: World health organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: A systematic review and meta-analysis. *BMC Infect Dis* 20: 62, 2020.
25. Lebel M: Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin. *Can J Infect Dis* 4: 148-152, 1993.
26. Crowther JR: The ELISA guidebook. *Methods Mol Biol* 149: III-IV, 1-413, 2000.
27. Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, Prakoeswa CRS, Astari L, Scollard DM, do Nascimento DC, *et al*: An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. *BMC Infect Dis* 18: 506, 2018.
28. MIMS: Drug information. Accessed: April 18, 2021. <https://www.mims.com/indonesia>.
29. Grüner N, Stambouli O and Ross RS: Dried blood spots-preparing and processing for use in immunoassays and in molecular techniques. *J Vis Exp* 97: 52619, 2015.
30. Richardus RA, van der Zwet K, van Hooij A, Wilson L, Oskam L, Faber R, van den Eeden SJF, Pahan D, Alam K, Richardus JH and Geluk A: Longitudinal assessment of anti-PGL-1 serology in contacts of leprosy patients in Bangladesh. *PLoS Negl Trop Dis* 11: e0006083, 2017.
31. Girdhar A, Kumar A and Girdhar BK: A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India. *Lepr Rev* 82: 46-54, 2011.
32. Yang D, Shui T, Miranda JW, Gilson DJ, Song Z, Chen J, Shi C, Zhu J, Yang J and Jing Z: *Mycobacterium leprae*-infected macrophages preferentially primed regulatory T cell responses and was associated with lepromatous leprosy. *PLoS Negl Trop Dis* 10: e0004335, 2016.
33. Lal V, Pal S, Haldar NK, Mandal PK and Srinivas G: What parents should know while their child is on MDT: Insights from a qualitative study in Eastern India. *Lepr Rev* 85: 81-84, 2014.